Search results for " Dose"

showing 10 items of 593 documents

Early mitochondrial dysfunction, superoxide anion production, and DNA degradation are associated with non-apoptotic death of human airway epithelial …

2002

It has been shown that bacterial exoproducts may induce airway epithelium injury. During the epithelial repair process, the respiratory epithelial cells no more establish tight junctional intercellular complexes and may be particularly susceptible to bacterial virulence factors. In this study, we analyzed the effect of Pseudomonas aeruginosa exotoxin A (ETA) at different periods of time and concentrations on 16 HBE 14o(-) human bronchial epithelial cells in culture conditions inducing a phenotype of repairing cells. ETA treatment for 24 and 48 h led to the killing of 40.0 +/- 5.7% and 79.0 +/- 1.4% of the cells, respectively, as determined by the dimethylthiazole 2,5 diphenyl tetrazolium br…

MESH: Cell DeathMESH: ADP Ribose TransferasesMESH : DNAClinical BiochemistryCellApoptosisMESH : Dose-Response Relationship DrugMitochondrion[SDV.MHEP.PSR]Life Sciences [q-bio]/Human health and pathology/Pulmonology and respiratory tractMembrane PotentialsMESH: Dose-Response Relationship Drugchemistry.chemical_compoundSuperoxidesMESH: Intracellular MembraneMESH : DNA FragmentationRespiratory systemEnzyme InhibitorsCells CulturedADP Ribose TransferasesMESH : Cell SurvivalCell DeathSuperoxideMESH: DNAMESH: BronchiCaspase InhibitorsMESH : BronchiMitochondriaMESH : Epithelial Cellsmedicine.anatomical_structureMESH: Cell SurvivalMESH: Enzyme InhibitorsMESH: Epithelial CellsMESH : ADP Ribose TransferasesIntracellularMESH: Cells CulturedPulmonary and Respiratory MedicineProgrammed cell deathCell SurvivalVirulence FactorsBacterial ToxinsExotoxinsBronchiDNA FragmentationRespiratory MucosaBiologyMicrobiologyNecrosisNasal PolypsMESH : Cells CulturedmedicineHumansMESH: DNA FragmentationMESH : Intracellular MembraneMolecular BiologyMESH : Enzyme InhibitorsMESH: HumansMESH: CaspasesDose-Response Relationship DrugMESH: ApoptosisMESH : HumansEpithelial CellsCell BiologyDNAIntracellular MembranesMESH: ExotoxinschemistryMESH: Bacterial ToxinsApoptosisMESH : ExotoxinsMESH : Cell DeathMESH : Bacterial ToxinsRespiratory epithelium[SDV.MHEP.PSR] Life Sciences [q-bio]/Human health and pathology/Pulmonology and respiratory tractMESH : CaspasesMESH : Apoptosis[ SDV.MHEP.PSR ] Life Sciences [q-bio]/Human health and pathology/Pulmonology and respiratory tract
researchProduct

Canakinumab for the Treatment of Autoinflammatory Recurrent Fever Syndromes.

2018

BACKGROUND: Familial Mediterranean fever, mevalonate kinase deficiency (also known as the hyperimmunoglobulinemia D syndrome), and the tumor necrosis factor receptor-associated periodic syndrome (TRAPS) are monogenic autoinflammatory diseases characterized by recurrent fever flares. METHODS: We randomly assigned patients with genetically confirmed colchicine-resistant familial Mediterranean fever, mevalonate kinase deficiency, or TRAPS at the time of a flare to receive 150 mg of canakinumab subcutaneously or placebo every 4 weeks. Patients who did not have a resolution of their flare received an add-on injection of 150 mg of canakinumab. The primary outcome was complete response (resolution…

Male0301 basic medicineInterleukin-1betaFamilial Mediterranean fever0302 clinical medicineMonoclonalChildMedicine(all)Mevalonate kinase deficiencySubcutaneousMedicine (all)Interleukin-1betaAntibodies MonoclonalGeneral MedicineFamilial Mediterranean FeverRecurrent feverChild PreschoolFemaleTumor necrosis factor alphaDrugInflammatory diseases Radboud Institute for Molecular Life Sciences [Radboudumc 5]medicine.drugAdultAdolescentFeverInjections SubcutaneousHereditary Autoinflammatory DiseasesAntibodies Monoclonal HumanizedAdolescent; Adult; Antibodies Monoclonal/administration & dosage; Antibodies Monoclonal/adverse effects; Antibodies Monoclonal/therapeutic use; Child; Child Preschool; Dose-Response Relationship Drug; Double-Blind Method; Familial Mediterranean Fever/drug therapy; Female; Fever/drug therapy; Hereditary Autoinflammatory Diseases/drug therapy; Humans; Injections Subcutaneous; Interleukin-1beta/antagonists & inhibitors; Male; Mevalonate Kinase Deficiency/drug therapy; Young AdultAntibodiesInjectionsDose-Response RelationshipYoung Adult03 medical and health sciencesAll institutes and research themes of the Radboud University Medical CenterDouble-Blind MethodGeneral & Internal MedicinemedicineHumansPreschoolAdolescent; Adult; Antibodies Monoclonal; Child; Child Preschool; Dose-Response Relationship Drug; Double-Blind Method; Familial Mediterranean Fever; Female; Fever; Hereditary Autoinflammatory Diseases; Humans; Injections Subcutaneous; Interleukin-1beta; Male; Mevalonate Kinase Deficiency; Young Adult; Medicine (all)030203 arthritis & rheumatologyDose-Response Relationship Drugbusiness.industryHereditary Autoinflammatory DiseasesHyperimmunoglobulinemia Dmedicine.diseaseCanakinumab030104 developmental biologyImmunologyMevalonate Kinase Deficiencybusiness
researchProduct

Obesogen effects after perinatal exposure of 4,4′-sulfonyldiphenol (Bisphenol S) in C57BL/6 mice

2016

International audience; Bisphenol A were removed from consumer products and replaced by chemical substitutes such as Bisphenol S (BPS). Based on their structural similarity, BPS may be obesogen like Bisphenol A in mice. Our objective was to determine the impact of BPS on lipid homeostasis in C57B1/6 mice after perinatal and chronic exposure. Pregnant mice were exposed to BPS via the drinking water (0.2; 1.5; 50 mu g/kg bw/d). Treatment began at gestational day 0 and continued in offspring up to 23-weeks old. Then, offspring mice were fed with a standard or high fat diet. The body weight, food consumption, fat mass and energy expenditure were measured. A lipid load test was performed to chec…

Male0301 basic medicineLeptinBisphenol S[ SDV.TOX ] Life Sciences [q-bio]/ToxicologyAdipose tissue010501 environmental sciencesToxicologyurologic and male genital diseases01 natural sciencesPolyethylene GlycolsMicechemistry.chemical_compoundPregnancyInduced ObesityHyperinsulinemiapériode perinataleObesogenSulfones2. Zero hungerLeptinHigh-Fat Dietsanté humaineLipidsEnergy-Balance3. Good healthSafe AlternativesobésitéAdipose TissuePrenatal Exposure Delayed Effects[SDV.TOX]Life Sciences [q-bio]/Toxicologybisphénol sFemalehormones hormone substitutes and hormone antagonistsmedicine.medical_specialtyOffspringDiet High-Fat03 medical and health sciencesInsulin resistancePhenolsInternal medicinemedicineAnimalshoméostasie lipidiqueObesityRNA MessengerTriglycerides0105 earth and related environmental sciencesDose-Response Relationship DrugAdiponectinTriglycerideInsulin-ResistanceBody WeightOverweightmedicine.diseasebisphenol S;food contaminant;perinatal exposure;low dose;obesogenPerinatal exposureMice Inbred C57BLFood contaminant030104 developmental biologyEndocrinologycontaminant chimiqueLow doseGlucoseMetabolismGene Expression RegulationchemistryIn-VitroObesogenAnalogs
researchProduct

Bispecific T-Cell Engager (BiTE) Antibody Construct Blinatumomab for the Treatment of Patients With Relapsed/Refractory Non-Hodgkin Lymphoma : Final …

2016

Purpose Blinatumomab is a CD19/CD3 BiTE (bispecific T-cell engager) antibody construct for the treatment of Philadelphia chromosome–negative acute B-lymphoblastic leukemia. We evaluated blinatumomab in relapsed/refractory B-cell non-Hodgkin lymphoma (NHL). Patients and Methods This 3 + 3 design, phase I dose-escalation study determined adverse events and the maximum tolerated dose (MTD) of continuous intravenous infusion blinatumomab in patients with relapsed/refractory NHL. Blinatumomab was administered over 4 or 8 weeks at seven different dose levels (0.5 to 90 μg/m2/day). End points were incidence of adverse events, pharmacokinetics, pharmacodynamics, and overall response rate. Results B…

Male0301 basic medicineOncologyCancer ResearchCD3 ComplexT-Lymphocytesmedicine.medical_treatmentMedizinLymphoma Mantle-CellLymphocyte Activation0302 clinical medicineRecurrenceGermanyhemic and lymphatic diseasesAntibodies BispecificMedicineMolecular Targeted TherapyInfusions IntravenousLymphoma FollicularLymphoma Non-HodgkinRemission InductionMiddle AgedLeukemiaTreatment OutcomeOncology030220 oncology & carcinogenesisFemaleBlinatumomabImmunotherapymedicine.drugAdultmedicine.medical_specialtyLymphoma B-CellMaximum Tolerated DoseAntigens CD19Antineoplastic AgentsDrug Administration Schedule03 medical and health sciencesPharmacokineticsRefractoryInternal medicineHumansAdverse effectbusiness.industryImmunotherapymedicine.diseaseLymphomaSurgery030104 developmental biologyPharmacodynamicsNervous System Diseasesbusiness
researchProduct

Fitness costs of increased cataract frequency and cumulative radiation dose in natural mammalian populations from Chernobyl

2015

AbstractA cataract is a clouding of the lens that reduces light transmission to the retina and it decreases the visual acuity of the bearer. The prevalence of cataracts in natural populations of mammals and their potential ecological significance, is poorly known. Cataracts have been reported to arise from high levels of oxidative stress and a major cause of oxidative stress is ionizing radiation. We investigated whether elevated frequencies of cataracts are found in eyes of bank voles Myodes glareolus collected from natural populations in areas with varying levels of background radiation in Chernobyl. We found high frequencies of cataracts in voles collected from different areas in Chernob…

Male0301 basic medicineVisual acuitygenetic structuresOffspringtaustasäteilyPhysiology010501 environmental sciencesRadiation DosageChernobyl Nuclear Accidentmedicine.disease_cause01 natural sciencesArticleIonizing radiationChernobylToxicology03 medical and health sciencesbackground radiationCataractskaihiRadiation IonizingMyodes glareolusmedicineAnimalsbank voleRadiation Injuries0105 earth and related environmental sciencesMammalsMultidisciplinarybiologyArvicolinaeRadiation dosemedicine.diseasebiology.organism_classificationeye diseasesfitness costs030104 developmental biologyChernobyl Nuclear AccidentArvicolinaecataractta1181Femalesense organsmedicine.symptomradiation doseOxidative stressScientific Reports
researchProduct

Antitumor activity of ipatasertib combined with chemotherapy: results from a phase Ib study in solid tumors

2020

Inhibidor d'AKT; Càncer avançat; Fase I Inhibidor de AKT; Cáncer avanzado; Fase I AKT inhibitor; Advanced cancer; Phase I Background This phase Ib study evaluated the safety, tolerability, pharmacokinetics, and preliminary efficacy of the oral AKT inhibitor ipatasertib and chemotherapy or hormonal therapy in patients with advanced or metastatic solid tumors to determine combined dose-limiting toxicities (DLTs), maximum tolerated dose, and recommended phase II doses and schedules. Patients and methods The clinical study comprised four combination treatment arms: arm A (with docetaxel), arm B [with mFOLFOX6 (modified leucovorin, 5-fluorouracil, and oxaliplatin)], arm C (with paclitaxel), and …

Male0301 basic medicinemedicine.medical_specialtyMaximum Tolerated Dosemedicine.medical_treatmentCàncer - Quimioteràpia:Otros calificadores::Otros calificadores::/efectos adversos [Otros calificadores]GastroenterologyAKT inhibitorPiperazinesMedicaments antineoplàstics - Efectes secundaris:neoplasias [ENFERMEDADES]03 medical and health scienceschemistry.chemical_compound0302 clinical medicineNeoplasmsInternal medicineAntineoplastic Combined Chemotherapy Protocols:Other subheadings::Other subheadings::/adverse effects [Other subheadings]medicineadvanced cancerHumansEnzalutamide:terapéutica::protocolos clínicos::protocolos antineoplásicos::protocolos de quimioterapia antineoplásica combinada [TÉCNICAS Y EQUIPOS ANALÍTICOS DIAGNÓSTICOS Y TERAPÉUTICOS]Adverse effectChemotherapybusiness.industryHematologyphase I:Therapeutics::Clinical Protocols::Antineoplastic Protocols::Antineoplastic Combined Chemotherapy Protocols [ANALYTICAL DIAGNOSTIC AND THERAPEUTIC TECHNIQUES AND EQUIPMENT]Oxaliplatin:Neoplasms [DISEASES]Pyrimidines030104 developmental biologyOncologyDocetaxelTolerabilityPaclitaxelchemistryResponse Evaluation Criteria in Solid Tumors030220 oncology & carcinogenesisbusinessmedicine.drugAnnals of Oncology
researchProduct

In the rat maximal dentate activation model of partial complex epilepsy, the anticonvulsant activity of levetiracetam is modulated by nitric oxide-ac…

2009

The effects of nitric oxide-active drugs on the anticonvulsant action of the antiepileptic drug levetiracetam in an experimental model of partial complex seizures named maximal dentate gyrus activation were studied in rats. Levetiracetam was given alone or in combination with 7-nitroindazole, a preferential inhibitor of neuronal nitric oxide synthase, or with L: -arginine, the precursor of nitric oxide synthesis. The maximal dentate activation parameters were the time of latency and the durations of maximal dentate activation and afterdischarge responses. The administration of levetiracetam showed an anticonvulsant effect that was increased when given in combination with 7-nitroindazole. Th…

Male7-NitroindazoleIndazolesLevetiracetamMaximal dentate activation - Nitric oxide - Levetiracetam - Modulation - 7-Nitroindazolemedicine.medical_treatmentNitric Oxide Synthase Type IPharmacologyArginineNitric OxideSettore BIO/09 - FisiologiaNitric oxideEpilepsychemistry.chemical_compoundEpilepsy Complex PartialmedicineAnimalsDrug InteractionsEnzyme InhibitorsRats WistarMaximal dentate activation Nitric oxide Levetiracetam Modulation 7-NitroindazoleBiological PsychiatryDose-Response Relationship DrugChemistryDentate gyrusPiracetammedicine.diseaseEffective dose (pharmacology)PiracetamRatsPsychiatry and Mental healthDisease Models AnimalDrug CombinationsAnticonvulsantNeurologyDentate GyrusAnticonvulsantsNeurology (clinical)Levetiracetammedicine.drugJournal of neural transmission (Vienna, Austria : 1996)
researchProduct

Comparison of the immunosuppressive efficacy of 6-mercaptopurine, azathioprine, cyclophosphamide and 036.5122 (Asta) on the primary and secondary imm…

1976

Two alkylating (cyclophosphamide and 036.5122 Asta) and two antiproliferative agents (6-mercaptopurine and azathioprine) have been compared for their immuno-suppressive potency on the primary and secondary humoral immune response of mice. If equitoxic dosages of the respective drugs are compared, the alkylating agents proved to be of much higher immunosuppressive potency than the antiproliferative agents. In non toxic dosages alkylating agents were able to completely inhibit a primary or secondary immune response, whilst a similar effect with antiproliferative drugs could not be obtained even within toxic dose ranges. Induction of immunological tolerance was possible only by use of the alky…

MaleAllergyErythrocytesTime FactorsDoseCyclophosphamidemedicine.medical_treatmentImmunologyAzathioprineViral Plaque AssayPharmacologyBiologyToxicologyLethal Dose 50MiceImmune systemAzathioprineImmune TolerancemedicineAnimalsPotencyPharmacology (medical)CyclophosphamidePharmacologyMercaptopurineImmunityImmunosuppressionmedicine.diseaseMercaptopurineImmunologyFemaleImmunosuppressive Agentsmedicine.drugAgents and Actions
researchProduct

Safety and efficacy of Temsirolimus in combination with Bendamustine and Rituximab in relapsed mantle cell and follicular lymphoma

2015

In this phase I/II study, we explored the combination of Temsirolimus with Bendamustine and Rituximab (BeRT) in patients with r/r follicular lymphoma (FL) or mantle cell lymphoma (MCL). Patients with 1-3 prior therapies received Bendamustine (90 mg/m(2), day 1+2) and Rituximab (375 mg/m(2), day 1) with Temsirolimus in doses from 25 to 75 mg added on day 1, 8, 15 of a 28-day cycle. Fifteen (11 MCL, 4 FL) patients were included in the phase I. Median age was 73 years and median pretreatment number was 2. No formal dose-limiting toxicity was observed. Dominant non-hematological side effects were fatigue in 11 (73%), nausea in 9 (60%), mucositis in 7 (47%) and vomiting in 6 patients (40%). Coug…

MaleBendamustineCancer Researchmedicine.medical_specialtyMaximum Tolerated DoseFollicular lymphomaLymphoma Mantle-CellNeutropeniaGastroenterologyAntibodies Monoclonal Murine-Derivedhemic and lymphatic diseasesInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineMucositisBendamustine HydrochlorideHumansProspective StudiesLymphoma FollicularAgedNeoplasm StagingSirolimusLeukopeniabusiness.industryRemission InductionHematologyMiddle AgedPrognosismedicine.diseaseTemsirolimusSurgerySurvival RateOncologyNitrogen Mustard CompoundsFeasibility StudiesFemaleMantle cell lymphomaRituximabNeoplasm Recurrence LocalSafetymedicine.symptomRituximabbusinessFollow-Up Studiesmedicine.drugLeukemia
researchProduct

Body mass index, basal insulin and glycemic control in children with type 1 diabetes treated with the advanced hybrid closed loop system remain stabl…

2022

BackgroundInformation on the influence of insulin treatment using advanced hybrid closed loop systems (AHCL) on body weight of young patients with type 1 diabetes (T1D) is scarce. The aim of this study was to observe whether there were any changes in body mass index (BMI) of children and adolescents with T1D treated using the Medtronic Minimed 780G AHCL after 1 year of follow up and to analyze potential associations between these changes and the insulin doses.Materials and methodsFor 50 children and adolescents (age 5.4-16.8 years, 24 (48%) boys, T1D for 3.9 ± 2.56 years) using an AHCL system anthropometric and AHCL data were collected prospectively. BMI Z-scores and two-week AHCL records o…

MaleBlood GlucoseAdolescenttype 1 diabetesEndocrinology Diabetes and MetabolismBody WeightGlycemic Controladvanced hybrid closed-loop systemBody Mass IndexBMIDiabetes Mellitus Type 1Insulin Infusion SystemsGlucosechildrenChild Preschooltime in rangetotal daily insulin doseHumansHypoglycemic AgentsInsulinFemalebasal insulinProspective StudiesChildFrontiers in endocrinology
researchProduct